AtriCure, Inc 8-K, filed Apr 8, 2021
AtriCure, Inc. (ATRC)
About this 8-K
AtriCure, Inc filed this 8-K on April 8, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
|
|
|
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 8, 2021, the Company issued a press release announcing that B. Kristine Johnson has been elected to Board Chair effective as of the 2021 Annual Meeting of Stockholders scheduled for May 20, 2021 (as may be postponed, continued or adjourned, the “Annual Meeting”). The press release also announces that Scott W. Drake and Mark R. Lanning will not stand for reelection to the Board at the Annual Meeting. A copy of the press release announcing these changes is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
No. |
| Description |
|
|
|
99.1 |
| |
104 |
| Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
| ATRICURE, INC. | |
|
|
|
|
Dated: | April 8, 2021 | By: | /s/ Angela L. Wirick |
|
|
| Angela L. Wirick |
|
|
| Chief Financial Officer |
|
Exhibit 99.1 |
April 8, 2021
AtriCure Names B. Kristine Johnson Board Chair
MASON, Ohio – (BUSINESS WIRE) – April 8, 2021– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced that Scott Drake and Mark Lanning will not stand for re-election at the end of their terms in May 2021.
“Kris’ experience and counsel have been impactful to AtriCure over the past four years, and I’m delighted that she will be serving in this new capacity, particularly as the Company executes on its many upcoming catalysts,” said Mr. Drake, current Board Chair.
Ms. Johnson has served on the company’s Board since May of 2017. She is President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States. In addition, Ms. Johnson serves on the Boards of Directors for ClearPoint Neuro, Inc., formerly MRI Interventions, ViewRay, Inc. (Nasdaq: VRAY), the University of Minnesota Foundation Investment Advisors, and several private entities. Ms. Johnson was previously employed for 17 years at Medtronic plc, serving most recently as Senior Vice President and Chief Administrative Officer from 1998 to 1999. Her experience at Medtronic also includes service as President of the Vascular Business and President of the Tachyarrhythmia Management Business.
Mr. Drake, the President and CEO of ViewRay, Inc., has served on AtriCure’s Board since September of 2013, and has served as Board Chair since May of 2018. Mr. Lanning has served on the Board since February of 2006 and has served on and as the Chair of a variety of Committees during his tenure.
“I want to thank Scott for his service and leadership on the Board, along with his guidance for our business,” said Michael Carrel, President and Chief Executive Officer. “He has helped me and the rest of the management team in profound ways, and we have been very fortunate to have him on the Board of Directors for the past eight years. I also want to thank Mark for his time on the Board, beginning with some of the very early days at AtriCure. He has been a steady hand in helping the company through a period of significant growth, and his financial acumen and support have been invaluable to our Company.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib-related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
CONTACTS:
Angie Wirick
Investor Relations
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Valerie Storch-Willhaus
Media Relations
Vice President, Corporate Marketing and Communications
(612) 605-3311
vstorch-willhaus@atricure.com